Pharmaceutical composition containing decoy and use of the same

Abstract

A pharmaceutical composition is provided for treatment and/or prevention of a disease, a disorder and/or a condition caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. Alternatively, the disease is a disease associated with eosinophilic abnormality (e.g., asthma, vascular diseases, allergic diseases, parasite diseases). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome, or the like.

1 . A method for the treatment of asthma comprising the step of administering a composition comprising: 
 an NF-κB decoy; and    a pharmaceutically acceptable carrier    
     
     
         2 . The method according to  claim 1 , wherein the NF-κB decoy comprises the nucleotide sequence of SEQ ID NO. 13.  
     
     
         3 .- 6 . (canceled)  
     
     
         7 . composition The method according to  claim 1 , wherein the pharmaceutically acceptable carrier is a hydrophilic polymer.  
     
     
         8 . The method according to  claim 1 , wherein the pharmaceutically acceptable carrier is a liposome.  
     
     
         9 . The method according to  claim 1 , wherein the asthma is caused by eosinophilic abnormality 
 a pharmaceutically acceptable carrier.    
     
     
         10 .- 14 . (canceled)  
     
     
         15 . The method according to  claim 1 , wherein asthma is selected from the group consisting of bronchial asthma, childhood asthma, allergic asthma, atopic asthma, steroid-resistant asthma (SRA), non-allergic asthma, intrinsic asthma, extrinsic asthma, aspirin-induced asthma, cardiac asthma, and infectious asthma.  
     
     
         16 .- 17 . (canceled)  
     
     
         18 . The method according to  claim 2 , wherein the NF-κB decoy comprises an oligonucleotide having a sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 5.